Last reviewed · How we verify

Standard of care_2

Ain Shams University · Phase 3 active Small molecule

Standard of care_2 is a Small molecule drug developed by Ain Shams University. It is currently in Phase 3 development for Various cancers. Also known as: Steroid.

This drug is a standard of care treatment.

This drug is a standard of care treatment. Used for Various cancers.

At a glance

Generic nameStandard of care_2
Also known asSteroid
SponsorAin Shams University
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

It is used to treat various conditions, but the exact mechanism is not specified.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Standard of care_2

What is Standard of care_2?

Standard of care_2 is a Small molecule drug developed by Ain Shams University, indicated for Various cancers.

How does Standard of care_2 work?

This drug is a standard of care treatment.

What is Standard of care_2 used for?

Standard of care_2 is indicated for Various cancers.

Who makes Standard of care_2?

Standard of care_2 is developed by Ain Shams University (see full Ain Shams University pipeline at /company/ain-shams-university).

Is Standard of care_2 also known as anything else?

Standard of care_2 is also known as Steroid.

What development phase is Standard of care_2 in?

Standard of care_2 is in Phase 3.

What are the side effects of Standard of care_2?

Common side effects of Standard of care_2 include Unknown.

Related